Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease

Ohgushi, Migiwa; Ogo, Naruhiko; Yanagihara, Toyoshi; Harada, Yukiko; Sumida, Kosuke; Egashira, Ayaka; Asoh, Tatsuma; Maeyama, Takashige; Yoshizawa, Seiji

doi:10.2169/internalmedicine.7971-21

Cited by 9 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 13 Accordingly, in cell line, it has been shown that tacrolimus inhibits the immunophilin pathway which SARS‐Co‐V replication depends on. 14 One case of interstitial pneumonitis after COVID‐19 treated with tacrolimus has been reported, 15 and a randomized, phase 2 clinical trial evaluating the efficacy and safety of a combination therapy of methylprednisolone and tacrolimus for severe pneumonia secondary to COVID‐19 is currently underway. 13 Our patient responded partially to the corticosteroid therapy but experienced a relapse when the PSL dosage was reduced to <30 mg.…”

Section: Discussionmentioning

confidence: 99%

Interstitial lung changes and persistent COVID‐19 in a patient with follicular lymphoma: A case report

Yomota,

Tanaka,

Kobayashi

et al. 2024

Respirology Case Reports

View full text Add to dashboard Cite

We herein report a case of interstitial lung changes in a patient with prolonged coronavirus disease 2019 (COVID‐19) with follicular lymphoma receiving rituximab and bendamustine who recovered after treatment with a combination therapy consisting of corticosteroids and immunosuppressive agents. There is currently no treatment strategy for prolonged pneumonitis following COVID‐19, which can be life‐threatening for immunocompromised patients. Thus, further investigation is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Interstitial lung changes and persistent COVID‐19 in a patient with follicular lymphoma: A case report

Yomota,

Tanaka,

Kobayashi

et al. 2024

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

“…Therefore, umifenovir is considered as one of the antiviral drugs that can effectively treat COVID-19 patients. Tacrolimus may be effective in the treatment of post-COVID-19 acute interstitial lung disease, but does not prevent the progression of pulmonary fibrosis ( Ohgushi et al, 2022 ).…”

Section: Methodsmentioning

confidence: 99%

Drug repositioning based on heterogeneous networks and variational graph autoencoders

Song

Lei

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Predicting new therapeutic effects (drug repositioning) of existing drugs plays an important role in drug development. However, traditional wet experimental prediction methods are usually time-consuming and costly. The emergence of more and more artificial intelligence-based drug repositioning methods in the past 2 years has facilitated drug development. In this study we propose a drug repositioning method, VGAEDR, based on a heterogeneous network of multiple drug attributes and a variational graph autoencoder. First, a drug-disease heterogeneous network is established based on three drug attributes, disease semantic information, and known drug-disease associations. Second, low-dimensional feature representations for heterogeneous networks are learned through a variational graph autoencoder module and a multi-layer convolutional module. Finally, the feature representation is fed to a fully connected layer and a Softmax layer to predict new drug-disease associations. Comparative experiments with other baseline methods on three datasets demonstrate the excellent performance of VGAEDR. In the case study, we predicted the top 10 possible anti-COVID-19 drugs on the existing drug and disease data, and six of them were verified by other literatures.

show abstract

“…The role of immunosuppression in persisting ILD remains unprecised. A case report reported no benefit of tacrolimus on a patient with post-COVID ILD [48].…”

Section: Treatment Optionsmentioning

confidence: 97%

Interstitial lung disease following coronavirus disease 2019

Vasarmidi

Ghanem

Crestani

2022

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of reviewThe aim of this review was to summarize the recent data concerning interstitial lung disease after COVID-19, a field where knowledge is evolving very quickly.Recent findingsIt has been found that a proportion of patients displayed fibrotic-like pattern on chest computed tomography shortly after COVID-19 pneumonia. Those lesions can potentially represent precursors of fibrosis, although most of them will resolve until 1 year postinfection. There was a wide range of the prevalence of post-COVID-19 interstitial lung disease detected in the literature, which can be attributed to the heterogeneous definition of lung abnormalities and the discrepancy of study design. The severity of acute COVID-19 disease has been linked to increased risk of residual imaging and functional abnormalities, while reduced DLco was the most common functional abnormality in long-term survivors. Studies indicated that pathophysiology of post-COVID interstitial lung disease shares common mechanisms with idiopathic pulmonary fibrosis. Regarding therapeutic strategies of post-COVID-19 interstitial lung disease, the role of immunosuppressive and antifibrotic treatment is currently under investigation.SummaryWe still need to learn about the natural history of COVID-19 disease, allowing for a better targeting of therapeutic interventions through a multidisciplinary approach.

show abstract

Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease

Cited by 9 publications

References 16 publications

Interstitial lung changes and persistent COVID‐19 in a patient with follicular lymphoma: A case report

Interstitial lung changes and persistent COVID‐19 in a patient with follicular lymphoma: A case report

Drug repositioning based on heterogeneous networks and variational graph autoencoders

Interstitial lung disease following coronavirus disease 2019

Contact Info

Product

Resources

About